|Videos|May 12, 2018

Hidden Challenges to Implementing Antimicrobial Stewardship Programs in the Outpatient Setting

Nathan A. Everson, PharmD, AAHIVE, shares some hidden challenges clinicians should address when implementing antibiotic stewardship interventions in the outpatient setting.

Nathan A. Everson, PharmD, AAHIVE, infectious disease pharmacist at Carilion Clinic, Roanoke Memorial Hospital, shares some hidden challenges clinicians should address when implementing antibiotic stewardship interventions in the outpatient setting.

Interview transcript (slightly modified for readability):

I think that when you are going from the inpatient to the outpatient side [one of the things you're] worried about is access, and it becomes a much bigger deal than you’re probably used to thinking on the inpatient side. We know we worry about that on discharge, but even getting to that first dose, you have to worry about patients being able to get the medication that’s the right choice for them, in terms of affordability and that sort of thing. That adds a whole layer of complexity that you’re not used to.

You’re also working with a lot less information about that patient, in terms of basing recommendations, sometimes you have a lot fewer laboratory values, you may not even have a great way of having a good dialogue with the patient necessarily. I think dealing with outpatient stewardship you have concerns that you sometimes get on the inpatient side, but maybe more so on the outpatient side. In terms of, people being comfortable with infectious disease sites, being current, people knowing what the most current medications are and having a great way of disseminating information to that outpatient setting. We’ve done a great job on the inpatient side of doing treatment guidelines and getting antibiograms in the hands of our providers and getting them on the same page in terms of the right way to treat infections. However, I think we don’t necessarily have a great way of communicating with a very large disparate group of outpatient practices in terms of getting people on that same page.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.